ALLMedicine™ Acquired Hemophilia Center
Research & Reviews 425 results
https://doi.org/10.1080/17474086.2021.1892483
Expert Review of Hematology; Franchini M, Schiavulli M et. al.
Mar 3rd, 2021 - Introduction: Acquired hemophilia A (AHA) is a rare autoimmune disease caused by autoantibodies that bind and inactivate factor VIII (FVIII), predisposing to a potentially life-threatening bleeding.Areas covered: The main epidemiological, clinical...
https://doi.org/10.1055/s-0040-1722294
Seminars in Thrombosis and Hemostasis; Thachil J
Mar 1st, 2021 - Potential Clues to the Pathogenesis of Acquired Hemophilia.|2021|Thachil J,|
https://doi.org/10.1055/s-0041-1725009
Thrombosis and Haemostasis; Takeyama M, Furukawa S et. al.
Feb 28th, 2021 - Emicizumab prophylaxis improves coagulation function in congenital hemophilia A, regardless of inhibitor presence. We recently reported that emicizumab enhanced the coagulant potentials, ex vivo, in plasmas from patients with acquired hemophilia A...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7899955
The American Journal of Case Reports; Regino CA, Alvarez JC et. al.
Feb 17th, 2021 - BACKGROUND Acquired hemophilia is a bleeding disorder mediated by an autoimmune process, in which antibodies against clotting factors are developed. This is a rarely suspected complex condition in which the initial manifestations are spontaneous b...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7883448
Journal of Medical Case Reports; Maeda K, Yamamoto S et. al.
Feb 15th, 2021 - Acquired hemophilia A is a rare coagulopathy caused by inhibitors of blood coagulation factor VIII. Patients with acquired hemophilia A have a higher mortality risk (5-10%) than those with congenital hemophilia. Moreover, there is no established e...
Guidelines 1 results
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2663620
Haematologica Huth-Kühne A, Baudo F et. al.
Apr 1st, 2009 - Acquired hemophilia A (AHA) is a rare bleeding disorder characterized by autoantibodies directed against circulating coagulation factor (F) VIII. Typically, patients with no prior history of a bleeding disorder present with spontaneous bleeding an...
Drugs 2 results see all →
Clinicaltrials.gov 437 results
https://doi.org/10.1080/17474086.2021.1892483
Expert Review of Hematology; Franchini M, Schiavulli M et. al.
Mar 3rd, 2021 - Introduction: Acquired hemophilia A (AHA) is a rare autoimmune disease caused by autoantibodies that bind and inactivate factor VIII (FVIII), predisposing to a potentially life-threatening bleeding.Areas covered: The main epidemiological, clinical...
https://doi.org/10.1055/s-0040-1722294
Seminars in Thrombosis and Hemostasis; Thachil J
Mar 1st, 2021 - Potential Clues to the Pathogenesis of Acquired Hemophilia.|2021|Thachil J,|
https://doi.org/10.1055/s-0041-1725009
Thrombosis and Haemostasis; Takeyama M, Furukawa S et. al.
Feb 28th, 2021 - Emicizumab prophylaxis improves coagulation function in congenital hemophilia A, regardless of inhibitor presence. We recently reported that emicizumab enhanced the coagulant potentials, ex vivo, in plasmas from patients with acquired hemophilia A...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7899955
The American Journal of Case Reports; Regino CA, Alvarez JC et. al.
Feb 17th, 2021 - BACKGROUND Acquired hemophilia is a bleeding disorder mediated by an autoimmune process, in which antibodies against clotting factors are developed. This is a rarely suspected complex condition in which the initial manifestations are spontaneous b...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7883448
Journal of Medical Case Reports; Maeda K, Yamamoto S et. al.
Feb 15th, 2021 - Acquired hemophilia A is a rare coagulopathy caused by inhibitors of blood coagulation factor VIII. Patients with acquired hemophilia A have a higher mortality risk (5-10%) than those with congenital hemophilia. Moreover, there is no established e...
News 19 results
https://www.mdedge.com/internalmedicine/article/209872/bleeding-disorders/new-consensus-recommendations-bleeding-acquired?channel=39313
Caleb Rans
Oct 10th, 2019 - New consensus statements, released by a group of 36 experts, provide specific recommendations related to monitoring bleeding and assessing efficacy of treatment in patients with acquired hemophilia. Svisio/Thinkstock A global survey was developed.
https://www.mdedge.com/ccjm/article/205517/hematology/unusual-cause-bruising/page/0/1?channel=50
Aug 1st, 2019 - FACTOR VIII INHIBITOR EVALUATION 2. What is the most likely underlying condition associated with this patient’s factor VIII inhibitor? Autoimmune disease Malignancy A medication Unknown (idiopathic) Acquired hemophilia A (AHA) is a rare disorder c.
https://www.mdedge.com/hematology-oncology/article/201468/bleeding-disorders/fviii/w-ratio-may-help-predict-relapse?channel=27970
Caleb Rans
May 22nd, 2019 - The FVIII/W (factor VIII:C/von Willebrand factor antigen) ratio appears to be a reliable biological marker to predict recovery and/or relapse in patients with acquired hemophilia A, according to a retrospective analysis. Marc Trossaert, MD, PhD, o.
https://www.mdedge.com/hematology-oncology/article/196298/bleeding-disorders/fxiii-replacement-may-improve-hemostasis?channel=27970
Caleb Rans
Mar 13th, 2019 - Measurement of factor XIII levels, followed by replacing deficiencies if found, may help to achieve sustained hemostasis in the management of bleeding in patients with acquired hemophilia A. Jameel Abdulrehman, MD, of the University of Toronto in.
https://www.reuters.com/article/us-shire-outlook/shire-cuts-2020-revenue-target-prepares-for-spin-off-of-adhd-drugs-idUSKBN1EX1I0
Jan 8th, 2018 - LONDON (Reuters) - Shire ditched its revenue target of $20 billion by 2020 on Monday due to increased generic competition and new drugs from rivals, saying it would split its rare disease and hyperactivity medicines businesses to boost performance...